OtherCommentary

Elastomer Change Out - Justification for minimizing the removal of elastomers in order to prevent cross contamination in a multiproduct facility.

Michael Parks, Niamh O'Dwyer, Jeremy Bollinger, Alan Johnson, Brian Goss, Ned Wyman, Adeyma Arroyo, Joseph Wood and Derek Willison-Parry
PDA Journal of Pharmaceutical Science and Technology September 2017, pdajpst.2016.007484; DOI: https://doi.org/10.5731/pdajpst.2016.007484

Article Information

pdajpst.2016.007484
DOI 
https://doi.org/10.5731/pdajpst.2016.007484
PubMed 
28928292
Published By 
Parenteral Drug Association (PDA)
Print ISSN 
1079-7440
Online ISSN 
1948-2124
History 
  • Received April 20, 2017
  • Accepted September 7, 2017
  • Published online September 19, 2017.

Article Versions

Copyright & Usage 
Copyright © 2017, Parenteral Drug Association

Author Information

  1. Michael Parks1 (michael.parks{at}pfizer.com),
  2. Niamh O'Dwyer1 (niamh.odwyer{at}pfizer.com),
  3. Jeremy Bollinger2 (jeremy.bollinger{at}biogen.com),
  4. Alan Johnson3 (johnsona{at}amgen.com),
  5. Brian Goss4 (brian.goss{at}lilly.com),
  6. Ned Wyman5 (wymann{at}medimmune.com),
  7. Adeyma Arroyo6 (adeyma{at}gene.com),
  8. Joseph Wood6 (wood.joseph{at}gene.com) and
  9. Derek Willison-Parry7,8 (derek{at}biophorum.com)
  1. 1 Pfizer;
  2. 2 Biogen;
  3. 3 Amgen;
  4. 4 Eli Lilly;
  5. 5 AstraZeneca;
  6. 6 Genetech Roche;
  7. 7 Biophorum
  1. ↵* Corresponding author; email: derek{at}biophorum.com

Cited By...

Back to top

In This Issue

Download PDF
Article Alerts
Email Article
Citation Tools
Elastomer Change Out - Justification for minimizing the removal of elastomers in order to prevent cross contamination in a multiproduct facility.
Michael Parks, Niamh O'Dwyer, Jeremy Bollinger, Alan Johnson, Brian Goss, Ned Wyman, Adeyma Arroyo, Joseph Wood, Derek Willison-Parry
PDA Journal of Pharmaceutical Science and Technology Sep 2017, pdajpst.2016.007484; DOI: 10.5731/pdajpst.2016.007484
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords